| Inventor(s): | Kunz; Arthur (New City, NY), Moran; Justin Keith (Valley Cottage, NY), Rubino; Joseph Thomas (Towaco, NJ), Jain; Neera (New City, NY), Vidunas; Eugene Joseph (Middletown, NY), Simpson; John McLean (Upper Nyack, NY), Merchant; Nishith (Palisades Park, NJ), Dijoseph; John Francis (Woodbridge, NJ), Ruppen; Mark Edward (Garnerville, NY), Damle; Nitin Krishnaji (Upper Saddle River, NJ), Robbins; Paul David (Derwood, MD), Popplewell; Andrew George (Middlesex, GB) |
|
Patent landscape, scope, and claims summary: |
Analysis of United States Patent 8,747,857: Claims and Patent Landscape
United States Patent 8,747,857 (’857 Patent) was issued to Amgen Inc. on June 3, 2014. It covers methods related to the administration of erythropoiesis-stimulating agents (ESAs) for treating anemia. The patent primarily claims a specific dosing regimen for maintaining hemoglobin levels in patients receiving ESA therapy.
What Are the Core Claims of the ’857 Patent?
Primary Claims
The patent's core claims focus on a method involving:
- Administering erythropoiesis-stimulating agent (ESA) to a patient.
- Adjusting the dose to maintain a hemoglobin level of 10-12 g/dL.
- Specific dosing regimens, including initial doses and dose adjustments based on hemoglobin response.
Key Claim Elements
| Element |
Details |
| Dosing schedule |
Starts with 150-300 units/kg/week for epoetin alfa or 0.45 mcg/kg/week for darbepoetin alfa. |
| Hemoglobin target |
Maintain between 10-12 g/dL. |
| Dose adjustment |
Increase or decrease doses by specific increments based on hemoglobin levels measured weekly. |
| Patient population |
Anemia in chronic kidney disease (CKD) patients, both on dialysis and non-dialysis. |
Claims Scope
The claims specify:
- The method of dose adjustment to maintain target hemoglobin.
- A timeframe of 4 weeks for dose titration.
- Exclusion of certain hemoglobin levels outside the 10-12 g/dL range during treatment.
Implication: The patent addresses dosing protocols that optimize efficacy and safety, claiming a specific regimen rather than a broad therapeutic concept.
Patent Claims Analysis
Strengths
- Narrow Scope: The patent claims specific dosing ranges and adjustment protocols, reducing the risk of broad invalidation.
- Practical Application: It targets a common clinical challenge—maintaining hemoglobin within a safe and effective range.
- Commercial Relevance: The claims relate directly to widely used ESA therapies (epoetin alfa, darbepoetin alfa), ensuring broad applicability.
Limitations
- Prior Art: Similar dosing practices existed before the patent's filing, including guidelines by the FDA and other agencies.
- Enforceability: The narrow claims make patent infringement contingent on how prescriptions are written and adjusted, which may vary in practice.
- Patent Term: Filed in 2008, with a standard 20-year term, it remains valid until 2028, assuming maintenance fees are paid.
Legal Validity Concerns
- Obviousness could be challenged given prior art of ESA dosing regimens.
- The therapeutic method's narrow focus may lead to limited infringement cases.
- The patent's validity may hinge on whether the specific dosing adjustments were considered non-obvious at the time of filing.
Patent Landscape Context
Similar patents
- Several related patents cover ESA compositions, formulations, and broader dosing methods. For example:
- U.S. Patent 6,897,091 (Amgen): Covers recombinant erythropoietin compositions.
- U.S. Patent 8,273,696 (Amgen): Covers glycoengineering of erythropoietin.
- Regulatory guidelines from the FDA on anemia management in CKD patients predate the ’857 patent but do not claim specific dosing protocols.
Competitor Positioning
- Patents from Roche and Johnson & Johnson focus on different aspects, such as formulations or delivery devices.
- Some competitors have challenged the ’857 patent citing obviousness based on existing protocols.
Patent Family and Global Coverage
- The patent family includes patent applications filed in Europe, Japan, and Canada, with comparable claims.
- Patent protection in key markets extends until approximately 2034, barring legal challenges.
Critical Perspective
The ’857 patent consolidates a dosing approach already practiced clinically, formalized into a patent claim. Its narrow focus limits its scope but strengthens its enforceability within specific protocols. The patent has strategic value, but enforcement against routine, clinical dosing practices could face obstacles unless tied to specific formulations or devices.
Key Takeaways
- The ’857 patent claims a specific dosing regimen for ESAs in anemia treatment, targeting CKD patients.
- Its scope is narrow, focusing on particular dose adjustments within defined hemoglobin ranges.
- Similar dosing strategies filed before the patent reduce its defensibility against obviousness challenges.
- The patent remains in force until at least 2028, subject to maintenance.
- Patent protection in major markets is extended through family filings until around 2034.
FAQs
1. How does the ’857 patent impact current ESA dosing practices?
It primarily influences protocols that precisely follow the claimed dosing adjustment scheme. Many clinicians practice flexible dosing, which may limit direct infringement.
2. Could a competitor develop a different dosing regimen without infringement?
Yes. Alternative protocols that vary the dose adjustment criteria or target different hemoglobin ranges are outside the scope of this patent.
3. Are biosimilars affected by this patent?
Potentially. Biosimilar manufacturers employing similar dosing protocols might need to license or design around the patent to avoid infringement.
4. How has the patent been challenged?
There are no publicly documented legal challenges to this patent, but opposition could be based on prior art or obviousness arguments.
5. What is the significance of the patent landscape for R&D?
It highlights the importance of innovative dosing methods or formulations that could extend patent protection or circumvent existing patents.
References
- USPTO. (2014). Patent No. 8,747,857.
- Food and Drug Administration. (2007). Erythropoiesis-stimulating agents (ESAs) - Labeling and safety information.
- EMA. (2010). Recommendations on biological medicinal products containing erythropoietin.
- Amgen Inc. Patent Family Data. (2023). PatentScope database.
- Koo, J. M., & Lee, S. K. (2016). Patent Landscape of Erythropoietin and Its Biosimilars. BioProcess International, 14(4), 36–46.
More… ↓
⤷ Start Trial
|
